

Customer Number: 000959

**DIVISIONAL-CONTINUATION APPLICATION TRANSMITTAL FORM
UNDER RULE 1.53(b) (former Rule 1.60)**

JCS 1.4 U.S. PTO
01/23/98

DOCKET NUMBER	ANTICIPATED CLASSIFICATION OF THIS APPLICATION:		PRIOR APPLICATION SERIAL NUMBER: 08/170,579	PRIOR APPLICATION FILING DATE: DECEMBER 20, 1993
TCI-028DV	CLASS: 435	SUBCLASS: 069.60	EXAMINER: B. CAMPELL	ART UNIT: 1819

ASSISTANT COMMISSIONER FOR PATENTS

BOX PATENT APPLICATION

WASHINGTON, DC 20231

CERTIFICATION UNDER 37 CFR 1.10

Date of Deposit: January 23, 1998Mailing Label Number: EM284254988US

I hereby certify that this 37 CFR 1.53(b) request and the documents referred to as attached therein are being deposited with the United States Postal Service on the date indicated above in an envelope as "Express Mail Post Office to Addressee" service under 37 CFR 1.10 and addressed to the Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

Nelson Barros
Name of Person Mailing Paper

Nelson Barros
Signature of Person Mailing Paper

Dear Sir:

This is a request for filing a continuation divisional application under 37 CFR 1.53(b), of pending prior application serial no. 08/170,579 filed on December 20, 1993, of Harry Meade; Daniel Pollock; Paul Ditullio entitled TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK.

1. Enclosed is a copy of the latest inventor signed application, including the oath or declaration as originally filed. The copy of the enclosed papers is as follows:

- 13 page(s) of specification
 3 page(s) of claims
 1 page(s) of abstract
 4 sheet(s) of drawing
 3 page(s) of declaration and power of attorney.

I hereby verify that the attached papers are a true copy of the prior complete application serial no. 08/170,579 as originally filed on December 20, 1993.

2. A verified statement to establish small entity status under 37 CFR 1.9 and 1.27, a copy of which is enclosed, was filed in the prior application and such status is still proper and desired (37 CFR 1.28(a)).

3. The filing fee is calculated below:

	NUMBER OF CLAIMS FILED	MINUS	NUMBER EXTRA
TOTAL *	18	**	20
INDEP. *	3	***	3
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS			

SMALL ENTITY		OTHER THAN A SMALL ENTITY	
RATE	FEES	OR RATE	FEES
x 11 =	\$.00	x 22 =	\$.00
x 41 =	\$.00	x 82 =	\$.00
+135 =	\$.00	+ 270 =	\$.00
BASIC FEE	\$.00	BASIC FEE	\$ 790.00
TOTAL	\$.00	TOTAL	\$ 790.00

- A1 sub D'
4. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 12-0080. A duplicate copy of this sheet is enclosed.
 5. A check in the amount of \$790.00 is enclosed for payment of the filing fee.
 6. Cancel in this application original claims _____ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
 7. A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claims in the prior application.)
 8. Amend the specification by inserting before the first line the sentences: "This application is a divisional application of serial no. 08/170,579 filed on December 20, 1993, Pending. The contents of all of the aforementioned application(s) are hereby incorporated by reference."
 9. Please abandon said prior application as of the filing date accorded this application. A duplicate copy of this transmittal is enclosed for filing in the prior application file. (May be used if signed by person authorized by §1.138 and before payment of base issue fee.)
 10. Transfer the drawings from the pending prior application to this application.
 11. Priority of application serial no. _____ filed on _____ in _____ is claimed under 35 U.S.C. §119.
 - The certified copy has been filed in prior application serial no. _____ filed on _____.
 - The certified copy will follow.
 12. The prior application is assigned of record to Genzyme Transgenics Corporation.
 13. A _____ month extension of time has been submitted in the parent application Serial No. in order to establish copendency with the present application.
 14. Also enclosed is/are:
 - a. A copy of the Power of Attorney from Darby & Darby P.C. to William G. Gosz, Esq. of the Genzyme Corporation.
 - b. A copy of the Power of Attorney from William G. Gosz, Esq. of the Genzyme Corporation to Lahive & Cockfield, LLP.
 - c. A copy of the Sequence Listing as filed in the prior application.
 15. The power of attorney in the prior application is to Lahive & Cockfield, LLP.
 - a. The power appears in the original papers in the prior application.
 - b. Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
 - c. A new power has been executed and is attached.
 16. Address all future communications (May only be completed by applicant, or attorney or agent of record) to Louis Myers at Customer Number: 000959 whose address is:


Lahive & Cockfield, LLP
28 State Street
Boston, Massachusetts 02109

17. Any requests for extensions of time necessary in a parent application for establishing copendency between this application and a parent application are hereby requested and the Commissioner is authorized to charge any fee associated with such an extension to Deposit Account No. 12-0080.
18. Pursuant to 37 CFR 1.821(e), the computer readable form of the sequence listing for this new application is to be identical with the computer readable form of application serial no. 08/170,579. Please use the computer readable form of application serial no. 08/170,579 in lieu of filing a duplicate computer readable form in this application. Pursuant to 37 CFR 1.821(f), the content of the paper copy of the sequence listing for this new application and the computer readable form of application serial no. 08/170,579 are the same.

January 23, 1998
Date

LAHIVE & COCKFIELD, LLP
28 State Street
Boston, Massachusetts 02109
Tel. (617) 227-7400

Louis Myers
Reg. No. 35,965
 inventor(s) filed under §1.34(a)
 assignee of complete interest
 attorney or agent of record



2025 RELEASE UNDER E.O. 14176